Lipocine is a specialty pharmaceutical company focused on developing innovative oral treatment alternatives for use in men’s and women’s health using its proprietary drug delivery technologies. Lipocine product development pipeline entails repositioning of established drugs with significantly improved patient compliance through an efficient 505(b) (2) regulatory pathway strategy.
LPCN 1021 is an oral testosterone replacement product candidate with positive topline Phase 3 efficacy results and is currently in an ongoing safety extension phase. The product is targeted to treat symptoms of low testosterone for hypogonadal men in need of testosterone replacement therapy. We believe LPCN 1021 is a safer alternative to current non-orals; reliably restores and maintains testosterone levels; is more convenient than currently marketed products and has the potential to improve patient’s therapy, adherence and retention.
LPCN 1111 is a novel next generation oral testosterone product candidate currently in Phase 2 with successful demonstration for once daily oral dosing for testosterone replacement therapy.
LPCN 1107 is targeted to be the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and is currently in Phase 1.
Company Growth (employees)
Lipocine was founded in 1997 and is headquartered in Salt Lake City, US
Lipocine Office Locations
Lipocine has an office in Salt Lake City
Salt Lake City, US (HQ)
202 675 Arapeen Dr
Lipocine Data and Metrics
Lipocine Financial Metrics
USD
Net income (Q1, 2017) | (4.9 m) |
EBIT (Q1, 2017) | (4.9 m) |
Market capitalization (15-Aug-2017) | 80.4 m |
Cash (31-Mar-2017) | 6.9 m |
Lipocine's current market capitalization is $80.4 m.
| USD | Y, 2013 | FY, 2016 |
|---|---|---|
R&D expense | 8.1 m | |
General and administrative expense | 10.4 m | |
Operating expense total | 10.7 m | 19.2 m |
EBIT | (10.7 m) | (19.2 m) |
Income tax expense | 55 k | (752) |
Net Income | (10.6 m) | (19 m) |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
R&D expense | 6 m | 3.2 m | 1.9 m | 3.2 m | 4.7 m | 2.7 m | 2.6 m | 1.5 m | 3.1 m |
General and administrative expense | 1 m | 871.8 k | 1.1 m | 1.1 m | 1.7 m | 4.4 m | 3.2 m | 1.4 m | 1.8 m |
Operating expense total | 7 m | 4.1 m | 3 m | 4.3 m | 6.4 m | 7.1 m | 5.8 m | 2.9 m | 4.9 m |
EBIT | (7 m) | (4.1 m) | (3 m) | (4.3 m) | (6.4 m) | (7.1 m) | (5.8 m) | (3.3 m) | (4.9 m) |
Income tax expense | (200) | (700) | (700) | ||||||
Net Income | (7 m) | (4.1 m) | (3 m) | (4.2 m) | (6.4 m) | (7 m) | (5.8 m) | (3.2 m) | (4.9 m) |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 45.3 m | 27.7 m | 20 m | 5.6 m |
Current Assets | 46 m | 27.9 m | 44.9 m | 27.2 m |
PP&E | 28.8 k | |||
Total Assets | 46.1 m | 28 m | 45.4 m | 27.3 m |
Accounts Payable | 1 m | 306.3 k | 507.1 k | 245.9 k |
Current Liabilities | 1.3 m | 1.6 m | 3.4 m | 1.3 m |
Total Liabilities | 1.3 m | |||
Additional Paid-in Capital | 92.7 m | 94.6 m | 128.5 m | 131.5 m |
Retained Earnings | (47.9 m) | (68.2 m) | (86.4 m) | (105.4 m) |
Total Equity | 26.4 m | 42 m | 26 m | |
Financial Leverage | 1.1 x | 1.1 x | 1.1 x |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 34.2 m | 31.7 m | 24.8 m | 38.3 m | 23.9 m | 14.1 m | 12.4 m | 4.7 m | 6.9 m |
Current Assets | 35.4 m | 32 m | 25 m | 44.1 m | 42.3 m | 38.6 m | 33.2 m | 29.4 m | 27.1 m |
Total Assets | 35.5 m | 32 m | 25.1 m | 53.8 m | 48.4 m | 38.8 m | 33.3 m | 29.6 m | 27.2 m |
Accounts Payable | 641.8 k | 399.1 k | 379.5 k | 398.8 k | 456.8 k | 1.1 m | 989 k | 865 k | 853.5 k |
Current Liabilities | 1.7 m | 2.1 m | 1.3 m | 1.7 m | 2.2 m | 3 m | 2.6 m | 1.6 m | 2.3 m |
Additional Paid-in Capital | 94 m | 94.2 m | 95 m | 127.6 m | 128.1 m | 129.3 m | 130 m | 130.5 m | 135.2 m |
Retained Earnings | (60.1 m) | (64.2 m) | (71.2 m) | (75.4 m) | (81.8 m) | (93.5 m) | (99.2 m) | (102.5 m) | (110.3 m) |
Total Equity | 33.8 m | 30 m | 23.7 m | 52.1 m | 46.2 m | 35.8 m | 30.8 m | 28 m | 24.9 m |
Financial Leverage | 1 x | 1.1 x | 1.1 x | 1 x | 1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (10.6 m) | (20.4 m) | (18.2 m) | (19 m) |
Depreciation and Amortization | 21.8 k | 14.6 k | 26.7 k | 32 k |
Accounts Payable | 668.8 k | (449.6 k) | 200.8 k | (261.2 k) |
Purchases of PP&E | (1.2 k) | (59.6 k) | (28.7 k) | (59.7 k) |
Cash From Financing Activities | 48.5 m | (255.1 k) |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (7 m) | (4.1 m) | (3 m) | (4.2 m) | (6.4 m) | (7 m) | (5.8 m) | (3.2 m) | (4.9 m) |
Accounts Payable | 641.8 k | 399.1 k | 379.5 k | 398.8 k | 456.8 k | 1.1 m | 989 k | 865 k | 853.5 k |
| Y, 2017 | |
|---|---|
Financial Leverage | 1.1 x |
Lipocine Market Value History
Market Position of Lipocine
Traffic Overview of Lipocine
Lipocine News and Updates
June 29, 2016
BRIEF-Lipocine gets complete response letter for LPCN 1021 from FDA
* Lipocine receives complete response letter (crl) for LPCN
1021 From U.S. Food And Drug Administration